Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Med Chem Lett ; 7(12): 1073-1076, 2016 Dec 08.
Article in English | MEDLINE | ID: mdl-27994740

ABSTRACT

Dipeptidyl nitroalkenes are potent reversible inhibitors of cysteine proteases. Inhibitor 11 resulted to be the most potent one with Ki values of 0.49 and 0.44 nM against rhodesain and cruzain, respectively. According to enzymatic dilution and dialysis experiments, as well as computational and NMR studies, dipeptidyl nitroalkenes are tightly binding covalent reversible inhibitors.

2.
J Am Chem Soc ; 138(27): 8332-5, 2016 07 13.
Article in English | MEDLINE | ID: mdl-27347738

ABSTRACT

We propose a structure-based protocol for the development of customized covalent inhibitors. Starting from a known inhibitor, in the first and second steps appropriate substituents of the warhead are selected on the basis of quantum mechanical (QM) computations and hybrid approaches combining QM with molecular mechanics (QM/MM). In the third step the recognition unit is optimized using docking approaches for the noncovalent complex. These predictions are finally verified by QM/MM or molecular dynamic simulations. The applicability of our approach is successfully demonstrated by the design of reversible covalent vinylsulfone-based inhibitors for rhodesain. The examples show that our approach is sufficiently accurate to identify compounds with the desired properties but also to exclude nonpromising ones.

3.
J Enzyme Inhib Med Chem ; 31(6): 1184-91, 2016 Dec.
Article in English | MEDLINE | ID: mdl-26572904

ABSTRACT

Novel rhodesain inhibitors were developed by combining an enantiomerically pure 3-bromoisoxazoline warhead with a 1,4-benzodiazepine scaffold as specific recognition moiety. All compounds were proven to inhibit rhodesain with Ki values in the low-micromolar range. Their activity towards rhodesain was found to be coupled to an in vitro antitrypanosomal activity, with IC50 values ranging from the mid-micromolar to a low-micromolar value for the most active rhodesain inhibitor (R,S,S)-3. All compounds showed a good selectivity against the target enzyme since all of them were proven to be poor inhibitors of human cathepsin L.


Subject(s)
Cysteine Endopeptidases/drug effects , Peptidomimetics/pharmacology , Carbon-13 Magnetic Resonance Spectroscopy , Proton Magnetic Resonance Spectroscopy
4.
ChemMedChem ; 10(9): 1484-7, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26179752

ABSTRACT

Dipeptidyl enoates were prepared through a high-yielding two-step synthetic route. They have a dipeptidic structure with a 4-oxoenoate moiety as a warhead with multiple reactive sites. Dipeptidyl enoates were screened against rhodesain and human cathepsins B and L, and were found to be potent and selective inhibitors of rhodesain. Among them (S,E)-ethyl 5-((S)-2-{[(benzyloxy)carbonyl]amino}-3-phenylpropanamido)-7-methyl-4-oxooct-2-enoate (6) was the most potent, with an IC50 value of 16.4 nM and kinact /Ki =1.6×10(6) M(-1) s(-1) against rhodesain. These dipeptidyl enoates display a reversible mode of inhibition at very low concentrations and an irreversible mode at higher concentrations. Inhibition kinetics data, supported by docking studies, suggest a dual mode of action via attack of cysteine thiolate at two reactive positions.


Subject(s)
Cysteine Endopeptidases/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Dipeptides/chemistry , Dipeptides/pharmacology , Cathepsin B/antagonists & inhibitors , Cathepsin L/antagonists & inhibitors , Chemistry Techniques, Synthetic , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/chemistry , Drug Evaluation, Preclinical/methods , Humans , Inhibitory Concentration 50 , Kinetics , Molecular Docking Simulation , Molecular Targeted Therapy/methods , Structure-Activity Relationship , Trypanocidal Agents/chemistry , Trypanocidal Agents/pharmacology , Trypanosomiasis, African/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...